
Apixaban
In large trials, apixaban prevented more strokes than warfarin in atrial fibrillation with less major bleeding, prevented more strokes than aspirin in people who could not take warfarin, treated leg and lung clots with less bleeding than standard therapy, and, in people who had already finished 6 to 12 months of treatment, prevented more repeat clots than a placebo. Its main risk is bleeding. St. John's wort is the most important supplement interaction; vitamin E, fish oil and chia need a conversation with your prescriber.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with atrial fibrillation not caused by a valve problem, people who have had a leg or lung blood clot, and people recovering from hip or knee replacement, when a prescriber recommends anticoagulation
Common dosing range
Set by your prescriber. The label dose for atrial fibrillation is 5 mg twice daily, or 2.5 mg twice daily for people with at least two of: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher
When to expect effects
Peak levels 3 to 4 hours after a dose; the effect wears off over about 24 hours, which is why missed doses matter
Watch out for
Boxed warnings: stopping early raises the risk of stroke and clots, and spinal or epidural bleeding can occur with spinal procedures. Serious bleeding can happen. Avoid St. John's wort, and talk to your prescriber before taking aspirin, NSAIDs, high-dose vitamin E or high-dose omega-3
What is it
Apixaban is a prescription blood thinner (anticoagulant) taken by mouth, sold under the brand name Eliquis. It belongs to the direct oral anticoagulants, sometimes called DOACs. The FDA label approves it to lower the risk of stroke and blood clots in adults with atrial fibrillation not caused by a heart valve problem, to prevent clots after hip or knee replacement, to treat clots in the legs (deep vein thrombosis) or lungs (pulmonary embolism) and lower the chance they come back, and, in children from birth onward, to treat clots and lower the chance they come back after at least 5 days of initial blood-thinner treatment. It is given at fixed doses; the label notes that standard clotting tests such as the INR are not useful for monitoring its effect.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
stroke prevention in atrial fibrillation (versus warfarin) Good Evidence | Moderate; 21% fewer strokes or emboli and 31% less major bleeding than warfarin | Adults with atrial fibrillation not caused by a valve problem and at least one added stroke risk factor | Protection while taking it; the anticoagulant effect wears off within about a day of the last dose |
stroke prevention in atrial fibrillation when warfarin is unsuitable (versus aspirin) Good Evidence | Large; about 55% fewer strokes or emboli than aspirin, with similar major bleeding | Adults with atrial fibrillation and stroke risk for whom warfarin is unsuitable | Protection while taking it |
treatment of leg and lung blood clots Good Evidence | Similar clot prevention to standard therapy, with about 69% less major bleeding | Adults with a new leg vein clot or pulmonary embolism | Treatment ran 6 months in the trial; benefit lasts only while it is taken |
preventing repeat clots after initial treatment Good Evidence | Large; about 7 fewer repeat clots per 100 people over a year | People who finished 6 to 12 months of treatment for a clot and are at continuing risk | Throughout the 12 months studied; benefit lasts only while it is taken |
stroke prevention in atrial fibrillation (versus warfarin)
- Effect
- Moderate; 21% fewer strokes or emboli and 31% less major bleeding than warfarin
- Best fit
- Adults with atrial fibrillation not caused by a valve problem and at least one added stroke risk factor
- Time
- Protection while taking it; the anticoagulant effect wears off within about a day of the last dose
stroke prevention in atrial fibrillation when warfarin is unsuitable (versus aspirin)
- Effect
- Large; about 55% fewer strokes or emboli than aspirin, with similar major bleeding
- Best fit
- Adults with atrial fibrillation and stroke risk for whom warfarin is unsuitable
- Time
- Protection while taking it
treatment of leg and lung blood clots
- Effect
- Similar clot prevention to standard therapy, with about 69% less major bleeding
- Best fit
- Adults with a new leg vein clot or pulmonary embolism
- Time
- Treatment ran 6 months in the trial; benefit lasts only while it is taken
preventing repeat clots after initial treatment
- Effect
- Large; about 7 fewer repeat clots per 100 people over a year
- Best fit
- People who finished 6 to 12 months of treatment for a clot and are at continuing risk
- Time
- Throughout the 12 months studied; benefit lasts only while it is taken
Evidence for 4 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
stroke prevention in atrial fibrillation (versus warfarin)
Disease adjunctIn the ARISTOTLE trial, 18,201 people with atrial fibrillation and at least one other stroke risk factor were randomly assigned to apixaban 5 mg twice daily or warfarin and followed for a median of 1.8 years. Stroke or systemic embolism occurred at 1.27% per year with apixaban versus 1.60% with warfarin (hazard ratio 0.79). Major bleeding was lower (2.13% versus 3.09% per year), hemorrhagic stroke was about halved (0.24% versus 0.47%), and death from any cause was slightly lower (3.52% versus 3.94%). Ischemic stroke alone did not differ significantly. This is one large, double-blind, industry-funded trial.
Bottom line: Apixaban prevented slightly more strokes than warfarin with less bleeding.
stroke prevention in atrial fibrillation when warfarin is unsuitable (versus aspirin)
Disease adjunctThe AVERROES trial randomly assigned 5,599 people with atrial fibrillation who could not or would not take warfarin to apixaban 5 mg twice daily or aspirin 81 to 324 mg daily. It was stopped early for clear benefit after a mean of 1.1 years: stroke or systemic embolism occurred at 1.6% per year with apixaban versus 3.7% with aspirin (hazard ratio 0.45). Major bleeding was similar (1.4% versus 1.2% per year), and the difference in deaths (3.5% versus 4.4% per year) was not statistically significant.
Bottom line: Apixaban prevented more than half of strokes compared with aspirin, without more major bleeding.
treatment of leg and lung blood clots
Disease adjunctIn the AMPLIFY trial, 5,395 people with an acute deep vein thrombosis or pulmonary embolism received apixaban (10 mg twice daily for 7 days, then 5 mg twice daily for 6 months) or standard enoxaparin injections followed by warfarin. Recurrent clots or clot-related death occurred in 2.3% versus 2.7%, meeting the test for noninferiority. Major bleeding was lower with apixaban (0.6% versus 1.8%), as was major plus clinically relevant bleeding (4.3% versus 9.7%).
Bottom line: Apixaban treats leg and lung clots as well as standard therapy with less bleeding.
preventing repeat clots after initial treatment
Disease adjunctAMPLIFY-EXT enrolled 2,486 people who had completed 6 to 12 months of anticoagulation for a clot and whose doctors were unsure whether to continue. Over 12 months, repeat clots or clot-related death occurred in 8.8% on placebo versus 1.7% on apixaban 2.5 mg and 1.7% on 5 mg twice daily. Major bleeding was 0.5% on placebo, 0.2% on 2.5 mg and 0.1% on 5 mg; clinically relevant nonmajor bleeding was somewhat higher on apixaban (3.0% and 4.2% versus 2.3%).
Bottom line: Continuing apixaban sharply cut repeat clots without more major bleeding.
How it works
How to take it
What to track
Bottom line: Your prescriber sets the dose; take it twice a day without gaps and check supplements first.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Higher risk of stroke and clots if apixaban is stopped early without another anticoagulant (boxed warning).
Spinal or epidural blood collections (hematomas) that can cause long-term or permanent paralysis in people having spinal or epidural anesthesia or a spinal puncture (boxed warning).
Serious and potentially fatal bleeding. The effect lasts at least 24 hours after the last dose; vitamin K and protamine are not expected to reverse it.
More clots than with warfarin in people with triple-positive antiphospholipid syndrome, where direct oral anticoagulants are not recommended.
Who should avoid it
- People with active pathological bleeding
- People who had a severe allergic reaction to apixaban
- People with prosthetic heart valves (not studied; use not recommended)
- People with triple-positive antiphospholipid syndrome
Pregnancy & breastfeeding
The Eliquis label lists use in pregnancy as not recommended. It says the limited data in pregnancy are not enough to judge the risk of birth defects or miscarriage, that treatment may increase bleeding during pregnancy and delivery and in the fetus and newborn, and that a shorter-acting anticoagulant may be considered as delivery approaches because of epidural risks. People who could become pregnant should discuss pregnancy planning with their prescriber. Breastfeeding: there are no data on apixaban in human milk; it accumulated in rat milk, and the label says breastfeeding is not recommended during treatment.
Interactions
St. John's wort strongly speeds up both CYP3A4 and P-glycoprotein, which clear apixaban. The Eliquis label names it among products to avoid with apixaban because it lowers apixaban levels and raises the risk of stroke and clots. If you take it, talk to your doctor or pharmacist promptly rather than stopping anything on your own.
Vitamin E has anticoagulant properties. In 566 people with atrial fibrillation on warfarin (mean age 73.6), those who bled had higher blood vitamin E levels and levels predicted bleeding, an association rather than proof; the authors said it is unknown whether this holds for newer anticoagulants such as apixaban. Talk to your doctor or pharmacist before taking a high-dose vitamin E supplement.
These drugs raise apixaban levels and bleeding risk. The label says to halve the apixaban dose for people on 5 mg or 10 mg twice daily, and to avoid the combination for people already on 2.5 mg twice daily. Clarithromycin is an exception that the label says needs no dose change.
These drugs lower apixaban levels and raise the risk of stroke and clots, and the label says to avoid using them together.
The label lists these among drugs that increase bleeding risk with apixaban. In ARISTOTLE, adding aspirin raised the bleeding rate on apixaban from 1.8% to 3.4% per year. Ask your pharmacist before using any over-the-counter pain reliever.
Omega-3 fats have raised concern about bleeding. A 2024 meta-analysis of 11 randomized trials in 120,643 people found no overall increase in bleeding with omega-3 (rate ratio 1.09, not significant), but high-dose purified EPA raised the relative risk of bleeding by about 50% with a small absolute increase. These trials did not focus on people taking apixaban. Tell the clinician who manages your apixaban about any fish oil, especially high-dose or prescription omega-3.
Chia is a food rich in fiber and plant omega-3 (ALA). In a 12-week trial in 20 adults with type 2 diabetes eating about 37 g a day, chia lowered von Willebrand factor, a clotting protein, by 21% without changing hemostatic safety tests. There are no studies in people taking apixaban, so the concern is theoretical; mention a daily chia habit to your doctor or pharmacist.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (2)
+ st. john's wort
highSt. John's wort strongly induces both CYP3A4 (apixaban's main metabolizing enzyme) and P-glycoprotein (its efflux transporter). Taken together, it speeds apixaban's breakdown and clearance, lowering blood levels and weakening clot protection, which raises the risk of stroke or thromboembolism.
+ fish oil
moderateApixaban is a direct factor Xa inhibitor that raises bleeding risk on its own. Omega-3 fatty acids in fish oil have a mild antiplatelet effect that can theoretically add to that risk. A 2024 meta-analysis of 11 randomized trials (120,643 people) found no overall increase in bleeding with omega-3, while high-dose purified EPA raised the relative risk of bleeding by about 50 percent, a small absolute increase (about 0.6 percent). The trials did not focus on people taking apixaban, so tell the prescriber about any fish oil and clear high-dose omega-3 with a clinician first.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Do I need to limit leafy greens or vitamin K on Eliquis?⌄
No vitamin K diet rule applies to apixaban the way it does to warfarin. The Eliquis label notes that vitamin K is not expected to affect apixaban's anticoagulant activity. A normal, balanced diet is fine; ask your pharmacist if you are switching from warfarin and are unsure.
Can I take fish oil with Eliquis?⌄
Tell your prescriber first. A 2024 meta-analysis found no overall increase in bleeding with omega-3 supplements, but high-dose purified EPA raised the relative bleeding risk by about 50%. Those trials were not specifically in people taking apixaban, so your prescriber can weigh your own bleeding risk.
Can I take St. John's wort with Eliquis?⌄
The Eliquis label says to avoid it. St. John's wort speeds up the clearance of apixaban and can lower its levels, raising the risk of stroke and clots. If you already take it, talk to your doctor or pharmacist promptly.
Is vitamin E safe with Eliquis?⌄
This page rates high-dose vitamin E as a high-severity interaction. Vitamin E has anticoagulant properties, and in people taking warfarin higher vitamin E levels were linked to more bleeding. It has not been studied with apixaban, so ask your doctor or pharmacist before taking a supplement.
What should I do if I miss a dose?⌄
The label says to take it as soon as you remember on the same day, then go back to your usual twice-daily schedule. Do not take two doses at once to make up for a missed one.
Can I take ibuprofen or aspirin with Eliquis?⌄
The label lists aspirin and NSAIDs such as ibuprofen and naproxen among drugs that increase bleeding risk with apixaban. Ask your doctor or pharmacist which pain reliever is appropriate for you.
References by claim
stroke prevention in atrial fibrillation (versus warfarin)
Granger et al., 2011 · PubMed (2011) link
stroke prevention in atrial fibrillation when warfarin is unsuitable (versus aspirin)
Connolly et al., 2011 · PubMed (2011) link
treatment of leg and lung blood clots
Agnelli et al., 2013 · PubMed (2013) link
preventing repeat clots after initial treatment
Agnelli et al., 2013 · PubMed (2013) link
Safety
Eliquis (apixaban) prescribing information · DailyMed (FDA label) link
Interaction: Vitamin E (high-dose supplements)
Pastori et al., 2013 · PMC (2013) link
Interaction: Fish oil (omega-3 supplements)
Javaid et al., 2024 · PMC (2024) link
Interaction: Chia seeds
Vuksan et al., 2007 · PubMed (2007) link
Track Apixaban with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
